Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Table 3 Ongoing clinical trials about multitarget inhibition in pancreatic adenocarcinoma

Combination	Target	Frequence of mutation1	Setting	Clinical trial identifier2	Expected end of accrual
Dovitinib	FGRFR + PDGFR + VEGFR	+, +, +	Phase II, + GEM and CAPE	NCT01497392	Sep-16
Trastuzumab + Erlotinib	EGFR2 + EGFR	+, +	Phase II, + GEM	NCT01204372	Apr-15
MEK162 + Ganitumab	MEK1 + IGF-1R	+, +	Phase II, multi-disease, chemorefractory	NCT01562899	Apr-15

GEM: Gemcitabine; MEK 1: Mitogen-activated extracellular signal regulated kinase 1; CAPE: Capecitabine.

¹To obtain this parameter, a mean between the frequency of somatic mutations in the target was calculated from the paper by Biankin et al[108] and Waddel et al[109], Figure 1. Three parameter were possible: +++ ≥ 75%, ++ > 50%, + ≤ 50%;

²Data Available from: URL: http// http://www.clinicaltrials.gov (last access 2015 May 24).